Trial reportEuropean heart journal. Cardiovascular pharmacotherapy2026
A Bayesian analysis of finerenone in heart failure with mildly reduced and preserved ejection fraction: a pre-specified analysis of FINEARTS-HF.
Trial report in European heart journal. Cardiovascular pharmacotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04435626 (A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Finerenone on Morbidity and Mortality in Participants With Heart Failure), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Finerenone on Morbidity and Mortality in Participants With Heart Failure (NYHA II-IV) and Left Ventricular Ejection Fraction ≥ 40% (LVEF ≥ 40%)
Who cites it
1 citing paper in PubMed.
- Innovation and constraints in cardiovascular pharmacotherapy.European heart journal. Cardiovascular pharmacotherapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
aimsThe non-steroidal mineralocorticoid receptor agonist (MRA) finerenone reduced heart failure events and cardiovascular death in patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) in a frequentist analysis of the FINEARTS-HF trial. We applied Bayesian methods including prior information to provide probabilistic estimates of efficacy and safety. The aim of this study was to estimate the probability of different magnitudes of treatment benefit with finerenone vs. placebo using Bayesian analysis of FINEARTS-HF. METHODS AND
resultsIn this pre-specified Bayesian analysis, we estimated treatment efficacy incorporating prior information in a robust meta-analytic predictive (MAP) prior using data from two finerenone trials (FIDELIO-DKD and FIGARO-DKD) and a steroidal MRA spironolactone (TOPCAT). We compared results using vague priors and informative MAP priors. The primary outcome was cardiovascular death and total heart failure events. Among 6001 patients, Bayesian analysis with vague priors confirmed the frequentist results of a reduction in the rate of the primary outcome [RR 0.83; 95% credible interval (CrI) 0.74-0.94]. Incorporating prior evidence increased the posterior probability of a ≥ 10% reduction in the primary event rate from 90% to 92%. The probability that finerenone reduced cardiovascular death was 80% (HR 0.93, 95% CrI: 0.79-1.10), and all-cause mortality was 85% (HR 0.94, 95% CrI: 0.83-1.06). Finerenone increased the probability of hyperkalaemia and decreased the probability of hypokalaemia.
conclusionThe non-steroidal MRA finerenone reduced the rate of cardiovascular death and total heart failure events under both frequentist and Bayesian inference methods. The probability of benefit exceeded 80% for both cardiovascular and all-cause mortality with finerenone. Trial Registration: ClinicalTrials.gov Identifier: NCT04435626.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.